Trade Report: Today, Aperio Group LLC invests in Illumina Inc. (ILMN) Shares

Today, Aperio Group LLC invests in Illumina Inc. (ILMN) Shares

Aperio Group LLC raised its stake in shares of Illumina Inc. (NASDAQ:ILMN) by 28.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,338 shares of the life sciences company’s stock after buying an additional 9,292 shares during the period. Aperio Group LLC’s holdings in Illumina were worth $7,691,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Physicians Financial Services Inc. raised its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock valued at $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock valued at $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Illumina during the second quarter valued at about $112,000. Ropes Wealth Advisors LLC raised its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock valued at $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 93.52% of the company’s stock.

Shares of Illumina Inc. (NASDAQ:ILMN) traded up 0.57% on Friday, reaching $135.19. The company had a trading volume of 342,958 shares. The company has a market capitalization of $19.86 billion, a PE ratio of 45.37 and a beta of 1.24. The company’s 50-day moving average is $140.46 and its 200-day moving average is $152.80. Illumina Inc. has a one year low of $127.10 and a one year high of $196.47.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.10. Illumina had a net margin of 18.72% and a return on equity of 23.76%. The company earned $607 million during the quarter, compared to analyst estimates of $628.06 million. During the same period in the previous year, the business earned $0.80 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Equities research analysts predict that Illumina Inc. will post $3.32 earnings per share for the current year.

Several analysts have issued reports on the company. First Analysis lowered Illumina from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $130.00 to $116.00 in a research note on Wednesday, November 2nd. CL King lowered Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Canaccord Genuity set a $135.00 price objective on Illumina and gave the company a “hold” rating in a research note on Wednesday, November 2nd. Wells Fargo & Co. reiterated a “market perform” rating and set a $137.50 target price (down previously from $150.00) on shares of Illumina in a research note on Wednesday, October 12th. Finally, Vetr upgraded Illumina from a “sell” rating to a “buy” rating and set a $198.61 target price on the stock in a research note on Monday, October 3rd. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $152.88.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $171.25, for a total transaction of $102,750.00. Following the completion of the sale, the director now directly owns 17,065 shares in the company, valued at $2,922,381.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert S. Epstein sold 300 shares of the company’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total transaction of $52,287.00. Following the sale, the director now owns 6,924 shares of the company’s stock, valued at $1,206,783.96. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Illumina Company Profile

Related posts

Leave a Comment